RWA Wealth Partners LLC acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 2,211 shares of the company’s stock, valued at approximately $220,000.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MRNA. First Pacific Financial bought a new stake in Moderna during the 3rd quarter worth approximately $27,000. Arlington Trust Co LLC grew its holdings in shares of Moderna by 4,833.3% in the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after acquiring an additional 290 shares in the last quarter. GPS Wealth Strategies Group LLC grew its holdings in shares of Moderna by 54.1% in the third quarter. GPS Wealth Strategies Group LLC now owns 513 shares of the company’s stock valued at $53,000 after acquiring an additional 180 shares in the last quarter. Archer Investment Corp grew its holdings in shares of Moderna by 71.2% in the third quarter. Archer Investment Corp now owns 534 shares of the company’s stock valued at $55,000 after acquiring an additional 222 shares in the last quarter. Finally, Parkside Financial Bank & Trust grew its holdings in shares of Moderna by 44.9% in the third quarter. Parkside Financial Bank & Trust now owns 565 shares of the company’s stock valued at $58,000 after acquiring an additional 175 shares in the last quarter. 75.33% of the stock is owned by institutional investors.
Insider Buying and Selling
In related news, insider Shannon Thyme Klinger sold 544 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $99.05, for a total value of $53,883.20. Following the transaction, the insider now owns 9,267 shares of the company’s stock, valued at $917,896.35. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, President Stephen Hoge sold 2,388 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $225,833.16. Following the transaction, the president now owns 1,515,898 shares of the company’s stock, valued at $143,358,473.86. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Shannon Thyme Klinger sold 544 shares of the stock in a transaction on Friday, March 8th. The shares were sold at an average price of $99.05, for a total value of $53,883.20. Following the completion of the transaction, the insider now directly owns 9,267 shares in the company, valued at approximately $917,896.35. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 124,954 shares of company stock worth $13,158,776. Corporate insiders own 15.70% of the company’s stock.
Wall Street Analyst Weigh In
View Our Latest Report on MRNA
Moderna Trading Up 1.7 %
Shares of MRNA stock opened at $107.97 on Friday. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $142.79. The business’s fifty day moving average is $102.54 and its 200 day moving average is $93.77.
Moderna (NASDAQ:MRNA – Get Free Report) last issued its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The company had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.53 billion. During the same quarter last year, the business posted $3.61 earnings per share. The firm’s revenue was down 44.9% compared to the same quarter last year. Equities research analysts forecast that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.
Moderna Profile
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Read More
- Five stocks we like better than Moderna
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- 3 Stocks Leading the U.S. Agriculture Comeback
- How to Use Stock Screeners to Find Stocks
- How to Use Put Debit Spreads to Profit From Falling Stocks
- When to Sell a Stock for Profit or Loss
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.